# Asthma

Asthma care depends on confirming variable expiratory airflow limitation, assessing current control and exacerbation risk, and selecting the lowest effective anti-inflammatory regimen while repeatedly addressing inhaler technique, adherence, triggers, and diagnostic alternatives.

**Clinical question:** How should clinicians confirm asthma, assess control, and individualize maintenance therapy and follow-up?

Updated: 2026-08-21T01:32:55.059840+00:00

## What matters in practice
- Confirm asthma when possible with objective evidence of variable expiratory airflow limitation; symptoms alone are nonspecific. [21][24]
- Spirometry before and after a short-acting bronchodilator is recommended when asthma is being considered in patients aged 5 years or older. [21]
- A traditional positive bronchodilator response is an increase in FEV1 or FVC of at least 12% and 200 mL; it supports asthma but does not by itself exclude COPD. [18]
- Treatment intensity should be guided by serial assessment of symptom control, lung function, exacerbations, inhaler technique, and adherence, with step-down to the minimum effective regimen after stability. [3][7]
- Inhaled corticosteroids are foundational controller therapy; in pregnancy, available data from nearly 40,000 pregnancies do not associate ICS exposure with increased malformations or adverse pregnancy outcomes. [4][11]

## Confirm variable airflow limitation before committing to long-term treatment

Symptoms establish suspicion; objective testing should establish or support the diagnosis.

Asthma symptoms overlap with other respiratory disorders, so a definitive diagnosis should pair a compatible clinical pattern with documented variable expiratory airflow obstruction whenever feasible. Spirometry with pre- and post-bronchodilator measurements is the primary diagnostic test. [21][24]

Obstructive physiology is suggested by a reduced FEV1/FVC or FEV1/FEV6 ratio. A normal examination or normal baseline spirometry does not exclude asthma, particularly when testing is performed outside symptomatic periods; no single test is adequate in all patients. [21]

If objective results and the clinical history conflict, avoid diagnostic closure. Prospective comparison of adult diagnostic algorithms found that established guideline pathways have important sensitivity and specificity limitations. [8]
- Obtain spirometry before and after a short-acting bronchodilator in patients aged 5 years or older when asthma is under consideration. [21]
- Document baseline obstruction, bronchodilator reversibility, symptom pattern, reliever use, activity limitation, nocturnal symptoms, and prior systemic corticosteroid-treated exacerbations. [21][22]
- When poor control persists despite treatment, reconsider alternative diagnoses and repeat objective assessment rather than automatically escalating therapy. [23]

### Bronchodilator reversibility

A commonly used positive bronchodilator response is an increase of at least 12% and 200 mL from baseline in either FEV1 or FVC. This finding supports reversible airflow limitation but does not reliably distinguish asthma from COPD. [18][20]
- One described testing approach administers albuterol 400 mcg by metered-dose inhaler, then repeats spirometry 10 to 20 minutes later; lower doses may be used when tachycardia or tremor is a concern. [18]
- Recent ERS/ATS interpretive guidance has used change greater than 10% of predicted value rather than the older 12% plus 200 mL criterion, so report the criterion used by the laboratory. [20]

### When spirometry is nondiagnostic

Additional objective evaluation may include fractional exhaled nitric oxide (FeNO), peak expiratory flow variability, or bronchial challenge testing, interpreted in the context of symptoms and spirometry. A diagnostic pathway cited for adults uses FeNO of 40 ppb or greater plus objective evidence of variable airflow limitation, or FeNO 25 to 39 ppb plus a positive bronchial challenge test. [23]
- For persistent diagnostic uncertainty with poor symptom control, repeat spirometry and objective measures after 6 to 10 weeks while reassessing symptoms and competing diagnoses. [23]
- Peak flow can help identify changing control and distinguish asthma-related breathlessness from physiologic or non-asthma breathlessness during pregnancy. [4]

*Objective findings used to support asthma in symptomatic adults; interpretation should be integrated with clinical context. [18][21][23]*

| Test | Supportive finding | Clinical interpretation |
| --- | --- | --- |
| Pre/post-bronchodilator spirometry | FEV1 or FVC increase at least 12% and 200 mL from baseline. [18] | Supports variable airflow limitation; does not independently distinguish asthma from COPD. [18] |
| Spirometry | Reduced FEV1/FVC or FEV1/FEV6 ratio. [21] | Supports airflow obstruction; assess reversibility and alternative causes. [21] |
| FeNO with objective testing | FeNO at least 40 ppb plus positive reversibility, peak-flow variability, or bronchial hyperreactivity; alternatively, FeNO 25-39 ppb plus positive bronchial challenge. [23] | Supports asthma in a cited adult diagnostic pathway. [23] |

## Separate current control from treatment requirement and future risk

Use serial measurements rather than symptom recall alone.

Asthma management should distinguish control from severity. Control incorporates symptoms, activity limitation, nocturnal awakening, reliever requirement, lung function, and exacerbations; severity reflects the treatment intensity required to maintain control. [6][22]

At each follow-up, assess symptom burden over the preceding 2 to 4 weeks, reliever use, activity limitation, nocturnal symptoms, exacerbations, spirometry or peak flow when available, inhaler technique, adherence, smoking exposure, and relevant triggers. Serial measures of control should drive step-up and step-down decisions. [3][16][22]

Persistent poor control despite therapy should trigger review of the diagnosis, adherence, device technique, tobacco smoke and other exposures, and comorbid or alternative causes before medication escalation. [4][23]
- Intermittent asthma has historically been characterized by symptoms and reliever need no more than 2 days per week, nocturnal awakening fewer than 2 times monthly, no activity limitation, and no more than one systemic corticosteroid-treated exacerbation in the prior year. [22]
- Poor inhaler technique is linked to difficult-to-treat asthma and increased risk of exacerbation and hospitalization. [4]
- Use an individualized written action plan so patients know how to increase treatment when symptoms worsen and when to seek urgent care. [16]

*High-yield follow-up domains for asthma treatment adjustment. [3][4][6][16][22]*

| Domain | What to review | Action implication |
| --- | --- | --- |
| Symptoms and function | Daytime symptoms, activity limitation, nocturnal awakening, reliever use. [6][22] | Persistent impairment warrants reassessment of contributors and treatment intensity. [3][22] |
| Future risk | Exacerbations and systemic corticosteroid use. [6][22] | Prior exacerbation burden should influence controller strategy and follow-up intensity. [6][22] |
| Treatment delivery | Adherence and inhaler technique. [4] | Correct modifiable barriers before labeling disease refractory or escalating therapy. [4] |
| Exposure and self-management | Tobacco smoke, irritants, allergens, action-plan understanding. [16] | Reduce avoidable exposures and reinforce self-management plan. [16] |

## Use anti-inflammatory controller therapy and tailor the reliever strategy

Select therapy according to control, exacerbation risk, age, access, and inhaler competence.

ICS are the foundation of asthma treatment and improve quality of life while reducing respiratory morbidity. [11] For mild persistent asthma, the 2020 NHLBI update recommends either daily low-dose ICS with as-needed SABA or concomitant as-needed low-dose ICS and SABA. [5]

Guideline approaches differ at the mildest steps. GINA no longer prefers SABA monotherapy and recommends either as-needed low-dose ICS-formoterol or ICS taken with SABA, whereas NHLBI continues to permit as-needed SABA for intermittent asthma. This is a meaningful management difference rather than interchangeable terminology. [5]

Use the minimum effective medication intensity that maintains stability. Once control is achieved, step-down is appropriate with close monitoring; do not step down without planned follow-up. [3][7]
- Do not use a LABA without an ICS-containing regimen for asthma; LABA safety warnings remain relevant to asthma care. [2]
- Symbicort is FDA-labeled for asthma in patients aged 6 years and older and is not indicated for relief of acute bronchospasm. [2]
- For asthma in patients aged 12 years and older, the Symbicort label specifies 2 inhalations of 80/4.5 or 160/4.5 twice daily; for ages 6 to younger than 12 years, it specifies 2 inhalations of 80/4.5 twice daily. [2]
- FDA-labeled Symbicort dosing should not be conflated with maintenance-and-reliever regimens; the supplied label excerpt states it is not indicated for acute bronchospasm. [2]

### Inhaled corticosteroid safety and pregnancy

For pregnancy, maintaining asthma control is clinically important because exacerbations and hypoxia threaten maternal and fetal health. ICS remain the mainstay of therapy; available evidence from nearly 40,000 pregnancies does not associate ICS use with increased malformations or other adverse pregnancy outcomes. [4]
- Beclomethasone, budesonide, and fluticasone have substantial pregnancy safety data. [4]
- Use the lowest ICS dose that maintains control where feasible; FeNO may help fine-tune ICS dosing. [4]

### Adverse effects and adherence

Local ICS adverse effects, including dysphonia, pharyngitis, candidiasis, and cough, can undermine adherence. Ask specifically about these effects when control deteriorates or refills are inconsistent. [7]
- Recheck device-specific technique at each meaningful treatment change and after an exacerbation. Poor technique is a modifiable contributor to hospitalization risk. [4]
- Avoid tobacco smoke and other relevant irritants as part of both prevention and disease management. [16]

*Selected treatment distinctions supported by the available sources. [2][5][7]*

| Clinical situation | Supported option or principle | Key limitation |
| --- | --- | --- |
| Mild persistent asthma | Daily low-dose ICS plus as-needed SABA, or as-needed concomitant low-dose ICS and SABA under 2020 NHLBI guidance. [5] | Assessment of adherence, technique, and control remains necessary before escalation. [3][4] |
| Lowest treatment steps | GINA favors as-needed low-dose ICS-formoterol or ICS with SABA rather than SABA monotherapy. [5] | This differs from NHLBI, which permits as-needed SABA for intermittent asthma. [5] |
| Stable control | Consider step-down to the minimum effective regimen with close monitoring. [3][7] | Do not discontinue surveillance; symptoms and exacerbations should guide subsequent adjustment. [3] |
| Symbicort maintenance treatment | FDA-labeled asthma dosing is 2 inhalations twice daily at age-appropriate strength. [2] | The product label states it is not indicated for acute bronchospasm. [2] |

## Assess exacerbations rapidly and distinguish rescue treatment from maintenance treatment

Hypoxemia and progressive airflow limitation require immediate severity assessment.

During an acute exacerbation, rapidly assess vital signs and oxygen saturation. Peak expiratory flow can help gauge severity and monitor response to treatment. [24] Do not use a maintenance inhaler labeled as not indicated for acute bronchospasm as the presumed rescue intervention. [2]

Systemic corticosteroids are used for acute asthma exacerbations and, less commonly, as maintenance therapy in severe asthma. Their frequent use is concentrated among patients with severe disease, emphasizing the need to identify preventable exacerbation drivers and optimize inhaled treatment delivery. [4][10]
- Treat acute episodes requiring intensive measures as an emergency; Symbicort is contraindicated as primary treatment of status asthmaticus or acute episodes requiring intensive measures. [1][2]
- After an exacerbation, reassess control, inhaler technique, adherence, trigger exposure, and the need for an updated action plan. [4][16]

*Immediate assessment priorities in acute asthma exacerbation. [1][2][24]*

| Priority | Practical action | Reason |
| --- | --- | --- |
| Physiologic assessment | Measure vital signs and oxygen saturation. [24] | Identifies acute instability and hypoxemia. [24] |
| Airflow assessment | Measure peak flow when feasible and use serial values to monitor response. [24] | Provides an objective estimate of exacerbation severity and trajectory. [24] |
| Medication selection | Do not use Symbicort as primary treatment for status asthmaticus or acute episodes requiring intensive measures. [1][2] | The product is contraindicated in that setting and is not labeled for acute bronchospasm relief. [1][2] |

## Common questions

### Can a normal spirometry result exclude asthma?

No. Asthma may not show obstruction or reversibility when the patient is tested outside an active period, and no individual test is sufficient in all cases. Consider repeat objective testing, peak-flow variability, FeNO, or bronchial challenge in an appropriate clinical context. [21][23]

### What bronchodilator response supports asthma?

A traditional positive response is an increase of at least 12% and 200 mL in FEV1 or FVC after bronchodilator administration. It supports variable airflow limitation but does not independently exclude COPD. [18][20]

### When should asthma therapy be stepped down?

After control is achieved and clinical stability is established, reduce treatment toward the minimum effective regimen with close monitoring. Serial symptom-control assessment should guide the decision and detect relapse. [3][7]

### Is inhaled corticosteroid therapy appropriate during pregnancy?

Yes, ICS remain the mainstay of asthma therapy in pregnancy. Available evidence from nearly 40,000 pregnancies does not associate ICS exposure with increased malformations or adverse pregnancy outcomes; use the lowest dose that maintains control where feasible. [4]

## References
1. highlights of prescribing information — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9c122b91-a11f-49ca-80bb-3eec5112db87
2. These highlights do not include all the information needed to use SYMBICORT safely and effectively. See full prescribing information for SYMBICORT.
 
      
SYMBICORT 
 ®(budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, for oral inhalation use
 
      
Initial U.S. Approval: 2006 — dailymed.nlm.nih.gov — https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a645756c-c692-4bc6-a858-7e7e249561bd&type=display
3. Asthma | Annals of Internal Medicine — annals.org — https://annals.org/aim/fullarticle/2752315/asthma?searchresult=1
4. Asthma management in pregnancy and lactation: A review of current evidence and best practice recommendations | npj Primary Care Respiratory Medicine — www.nature.com — https://www.nature.com/articles/s41533-026-00491-9
5. Treatment for mild asthma: What matters to providers — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1081120626000967
6. Treatment of Asthma - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/treatment-of-asthma
7. Asthma management: Are GINA guidelines appropriate for daily clinical practice? — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1471441805000587
8. Asthma diagnosis: a comparison of established diagnostic guidelines in adults with respiratory symptoms — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2589537024003924
9. The quality of paediatric asthma guidelines: evidence ... — academic.oup.com — https://academic.oup.com/fampra/article/41/4/460/7169412
10. Systematic Literature Review of Systemic Corticosteroid Use ... — academic.oup.com — https://academic.oup.com/ajrccm/article/201/3/276/8496422
11. Association of Dose of Inhaled Corticosteroids and Frequency ... — academic.oup.com — https://academic.oup.com/ajrccm/article/211/1/54/8513341
12. 2020 NAEPP Guidelines Update and GINA 2021—Asthma ... — www.jaci-inpractice.org — https://www.jaci-inpractice.org/article/S2213-2198(21)01183-1/fulltext
13. Asthma Guidance: Options for Individualized Care — www.jaci-inpractice.org — https://www.jaci-inpractice.org/article/S2213-2198(21)01200-9/fulltext
14. Improving Asthma Management Through a Quality ... — www.jaci-inpractice.org — https://www.jaci-inpractice.org/article/S2213-2198(25)01122-5/fulltext
15. Improving the Delivery of Quality Evidence-Based Inpatient ... — publications.aap.org — https://publications.aap.org/pediatrics/article/157/6/e2025073834/207442/Improving-the-Delivery-of-Quality-Evidence-Based
16. Asthma — www.who.int — https://www.who.int/news-room/fact-sheets/detail/asthma
17. Global Initiative for Asthma Strategy 2021 — www.jaci-inpractice.org — https://www.jaci-inpractice.org/article/S2213-2198(21)01064-3/fulltext
18. Spirometry and Bronchodilator Test — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5392482
19. Assessment of Airway Bronchodilation by Spirometry Compared to Airway Obstruction in Young Children with Asthma - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4917687
20. Bronchodilator response as an independent predictor of severity in bronchiectasis - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12603552
21. Section 3, Component 1: Measures of Asthma Assessment and Monitoring - Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK7230
22. Guidance on the diagnosis and management of asthma ... - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4765426
23. Asthma: diagnosis, monitoring and chronic asthma management - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK560178
24. Asthma - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK430901

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.